In recent years, increased attention has been focused on antidepressant-associated sexual dysfunction, largely because of the widespread use of serotonin-specific reuptake inhibitors (SSRIs) and the recognition that such side effects can have a negative impact on treatment compliance. Data suggest that serotonergic antidepressants are associated with delayed ejaculation and anorgasmia, although these sexual problems are also linked to depression and to age. In this review, we discuss central mediators of normal orgasmic functioning and dysfunction, the relationship between depression and sexual dysfunction, possible mechanisms for SSRI-associated sexual dysfunction, and evolving treatment strategies.
Introduction
Sexual dysfunctions are especially prevalent among depressed patients. The interaction between comorbid sexual and depressive disorders has clinical implications for diagnosis, course and treatment of both conditions. In recent years, there has been significant progress in the basic research and clinical therapeutics of sexual disorders, with major advances in our understanding of the mechanisms of sexual response and the effects of pharmacologic agents on sexual desire, arousal and orgasm. Such progress has stimulated the development of the field of sexual medicine, and represents a significant shift in focus for a field that had traditionally been dominated by psychodynamic and behavioral paradigms and treatments. In parallel with the more medical approach to sexual dysfunction, the widespread use of psychotropic medications, and particularly serotonergic antidepressants, has introduced most psychiatrists to the complex problem of iatrogenic sexual dysfunction, particularly anorgasmia.
Delayed ejaculation (DE) and associated anorgasmia are dysfunctions of the climax phase of sexual response for which there are currently few treatment options available. Behavioral therapies have not been shown to be effective in treating this condition, and there are no pharmacological treatments with documented efficacy. Although DE is generally uncommon, it affects at least one-fourth of men who are taking serotonin-specific reuptake inhibitor (SSRI) antidepressants. 1 Antidepressant-induced DE can have a large impact on patients' satisfaction with their antidepressant treatment regimen, can promote medication non-compliance and subsequent depressive relapse, and is associated with reduced quality of life and relationship satisfaction. In this article, we will consider the relationship between male climax phase disorders and depression, placing particular emphasis on medicationinduced ejaculatory delay.
Normal orgasmic function
There are four overlapping phases of sexual function: (1) drive, (2) arousal, (3) climax, marked by emission, orgasm and ejaculation and (4) resolution. Emission, orgasm and ejaculation are distinct events modulated primarily by the sympathetic nervous system. Emission involves smooth muscle contraction and seminal fluid secretion from the seminal vesicles and prostate, followed by bladder neck closing (to prevent retrograde ejaculation) and rising pressure in the seminal bolus. With this rising pressure, the sensation of ejaculatory inevitability is experienced. Ejaculation is the reflex-induced expulsion of semen from the urethra. Orgasm is the cognitive experience of pleasure that coincides with ejaculation. 2, 3 Sensory receptors on the glans trigger afferent nerves that pass through the penile dorsal nerve into the spinothalamic tract and to the thalamus and sensory cortex. From these central nervous system (CNS) regions, efferent nerves run through the anterolateral column of the sympathetic ganglia at T 12 -L 3 . Emission is mediated by the central release of norepinephrine (NE), together with the local release of oxytocin, endothelin and adenosine triphosphate. The ejaculatory reflex arc begins with afferents at the glans and urethra, which are primarily parasympathetic. Central serotoninergic inputs suppress, and D 2 dopaminergic inputs facilitate the ejaculatory reflex, whereas local nitric oxide (NO) and carbon monoxide modulate the reflex.
Orgasmic dysfunction
DE reflects an inhibition of the ejaculatory reflex. Men with DE may be able to ejaculate with great effort and after a prolonged intercourse, or be unable to ejaculate at all in some circumstances. Men with DE typically experience persistent difficulty in attaining orgasm (i.e., the perception of erotic pleasure) despite adequate physical and erotic stimulation. The condition may be specific to partnered sex, or to certain partners. The prevalence appears to be low: in general population studies, the range is 1-4% of sexually active men. 3, 4 The factors that have been consistently shown to be associated with DE are age, depression and medication use. 3, 4 Men require more physical erotic stimulation with age, giving rise to progressive, ageassociated ejaculatory delay. 4, 5 Other less common etiologies include surgical disruption of the sympathetic nervous system, for example, prostatectomy, retroperitoneal lymph node dissection, radical extirpative surgery of the pelvis; diseases that interfere with sympathetic neurotransmission, for example, diabetic neuropathy, multiple sclerosis, alcoholic neuropathy; and the use of alcohol or narcotics. Although we will concentrate here on the role of psychopharmacological factors, particularly monoaminergic regulators of climax, it is likely that in many individuals, age and other factors confer a vulnerability to SSRI-related sexual dysfunction.
CNS mediators of sexual function
Most neurotransmitters with central effects on sexual function also influence the peripheral nervous system control of genital response. Moreover, there is a balance of interactions -central and peripheral -between neurotransmitters, such as monoamines and other neuromodulators, such as NO and sex steroids. Localizing the sexual effects of neuropharmacologic manipulations is therefore difficult.
Catecholamines appear to have stimulatory effects on sexual behavior. It was reported in the 1970s that dopaminergic drugs given to Parkinsonian patients appeared to be pro-sexual, and clinical consensus is that dopamine agonists increase sexual desire and erectile function. In rats, experimental data confirm that dopamine agonists increase mounting and reduce the latency to ejaculation. 6 Dopamine release in the medial preoptic area (MPOA) appears to stimulate increased copulatory rate and efficiency. Notably, the presence of testosterone has been shown to be permissive for dopamine release in the MPOA, probably mediated through NO production. 7 Dopamine antagonists inhibit sexual functioning, particularly orgasm. NE levels increase during sexual activity, and are positively correlated with arousal -increasing dramatically at orgasm, and then decreasing precipitously (in men, not women) to baseline by 2 min post-orgasm.
In contrast to the activating effects of catecholamines, serotonin tends to inhibit sexual behavior. In monkeys, 5HT-1C/1D agonists inhibit sexual behavior. In male rats, activation of the 5HT-1A receptor lowers the threshold for ejaculation, whereas activation of 5HT-1B and 5HT-1C and antagonism of 5HT-2, all inhibit sexual behavior. 8 The influence of monoamines on sexual function provide the best theoretical framework for understanding the sexual effects of psychotropic medications. Tricyclic antidepressants (TCAs) and dual reuptake inhibitors (e.g., venlafaxine and duloxetine) block the reuptake of serotonin and NE. Monoamine oxidase inhibitors (MAOIs) increase levels of serotonin, NE and dopamine. Although SSRIs have fewer secondary receptor effects, they also appear to inhibit dopamine neurotransmission, increase prolactin and inhibit NO synthase. 9 Overall, serotonergic activity, particularly at 5HT-1B/1C/1D, appears to predict an inhibition of sexual functioning. In contrast, the antidepressants with mechanisms of action that suggest a theoretical advantage include the following: bupropion, which inhibits dopamine and NE reuptake; 10 mirtazapine, which blocks 5HT-2A and 5HT-3 receptors (that are likely to inhibit orgasm); and nefazodone, which blocks the 5-HT2 receptor.
Medication-induced orgasmic dysfunction
Many prescription and non-prescription drugs with diverse pharmacologic properties have been reported to induce sexual dysfunction, particularly antihypertensives, antiulcer drugs, alcohol, sedative/hypnotics, mood stabilizers, antipsychotics and antidepressants. Yet, most of these reports have been anecdotal and have not reliably identified the phase of sexual response that is impaired. More importantly, none has clearly distinguished the effects of the medication from the underlying illness. This is particularly important in assessing the sexual effects of psychotropic agents, as such effects should be considered in the context of behavioral changes in the underlying psychiatric condition associated with therapeutic actions of the drug.
With the introduction and widespread use of SSRIs, the issue of medication-associated sexual dysfunction has assumed greater clinical significance, particularly with respect to treatment compliance and quality of life concerns. Daily antidepressants may cause sexual side effects in the drive phase (e.g., decreased libido -though this is difficult to distinguish from the decrease in sexual satisfaction associated with pervasive anhedonia); the arousal phase (e.g., erectile dysfunction (ED) -though the relation to pre-existing organic factors and to depressive illness complicates this association) and/or the climax phase (e.g., DE with or without anorgasmia). With daily serotonergic medications, DE appears to be most common, followed by decreased libido, and then arousal difficulties (see Rosen et al. 9 for review). Indeed, although low libido and ED are reported during SSRI treatment, the rates are not substantially different from base rates in the general population, 11 whereas consistently more than one-fourth of men taking SSRIs report problems occurring during the climax phase, and such problems are far less common in the general population. 9 Sexual dysfunction is reported somewhat less frequently with MAOIs, even less with TCAs, and rarely with nefazodone, bupropion or mirtazepine.
There are no published studies that have focused specifically on SSRI-related DE in men. In two large, influential studies in which the prevalence of antidepressant-associated sexual dysfunction was carefully addressed, male-specific data were not reported. In the first, a cross-sectional, observational study of 6297 patients (1763 men) were assessed in primary care settings; the prevalence of antidepressant-associated sexual dysfunction ranged from 7 to 30%, and bupropion was 4-6 times less likely to cause sexual dysfunction than the SSRIs. 12 In a second that included 1022 outpatients (412 men), the rates of sexual dysfunction in the entire sample were as follows: mirtazapine 24%, nefazodone 8%, amineptine 7%, meclobemide 4% and SSRIs from 58 to 73%. 13 When patients who had SSRI-associated sexual dysfunction were switched to a non-SSRI, 65-80% of patients improved, whereas only 10% who were switched to paroxetine improved. Again, because data were not reported for male DE specifically, it is difficult to extrapolate from these 'mixed-gender' data.
Depressive illness and sexual dysfunction
Separate from the effects of medication, depression itself can have an impact on sexual function. For example, there can be direct neurobiological effects, such as the reversible loss of erectile function in a subset of depressed men. 14 There can also be indirect effects through the disruption of social and interpersonal relationships. We know of no systematically collected data that address such interactions with respect to DE.
Impact of depression on sexual function
Loss of libido is considered a classic vegetative symptom of major depressive disorder (MDD) and has played a prominent role in psychological formulations of depressive illness. Systematically collected data confirm that MDD is associated with decreased libido 15 and diminished erectile function (including impaired nocturnal penile tumescence), [16] [17] [18] but there are few studies of unmedicated depressed patients. In a recent survey of sexual function that included 13 618 men, depression was consistently associated with DE. 4 In the Zurich Cohort study, 591 subjects have been followed for 15 years, and data collected from three interviews when the subjects were 28-35 years old. Overall, sexual dysfunction was diagnosed in 63% of depressed patients receiving medication, 45% of unmedicated depressed patients and 26% of nondepressed controls. 19, 20 Kennedy et al. 21 described the sexual functioning of 67 unmedicated depressed men who presented consecutively to an outpatient psychiatric clinic. Mean age of enrolled men was 40.4 years (s.d. ¼ 11.5), 43% were married, most had recurrent, chronic depression and mean HAM-D score was 22 (s.d. ¼ 4). Notably, one-fourth of the men reported no sexual activity in the previous month. Among the 41 sexually active men, there was a high prevalence of impairment in every phase of sexual functioning. For example, a decrease in sexual interest, fantasy and masturbation was evident in almost half the men; erectile problems were common, including fewer spontaneous erections (22%), decreased ability to maintain an erection (46%) and less vigorous erections (43%). Ejaculation was delayed in 9/41 (22%). Risk factors for DE included fewer Ejaculatory dysfunction and depression S Seidman S35 previous depressive episodes, and later age of onset of MDD.
In the ELIXIR study, Bonierbale et al. 22 recruited 4557 depressed patients (1958 men) in France from primary-care providers and community psychiatrists, and excluded those with sexual dysfunction before the onset of depression. About two-thirds were taking an antidepressant at the time of enrollment. Among the men, 75% reported sexual dysfunction (45% reported it spontaneously, the remainder after direct questioning). Notably, 65% of patients not receiving antidepressant medication reported sexual dysfunction, compared to 71% of those receiving antidepressant medication. Medication-induced sexual dysfunction appeared to primarily impact orgasm: DE was reported by 17% of men taking antidepressants, and 8.2% of those not taking antidepressants (Po0.001).
Impact of sexual dysfunction on mood
The link between sexual function and mood has not been well characterized, and there are no published data specific to DE. There is, however, suggestive evidence that a large proportion of individuals who present with sexual dysfunction have high levels of depression and anxiety. For example, in a large descriptive study, investigators carefully assessed comorbid psychiatric conditions among men presenting to the Johns Hopkins Sexual Behaviors Consultation Unit from 1976 to 1979 (N ¼ 199) and from 1984 to 1986 (N ¼ 223). 23 Overall, men with sexual dysfunction had high levels of depressive, somatic and anxious symptoms and scored very high on measures of overall psychological distress (e.g., using one well-validated instrument that measures such distress, these men scored in the 92nd percentile of the normative population).
To assess the relationship between depression and ED, we conducted a placebo-controlled, parallel-group, double-blind study of 50-100 mg of sildenafil or placebo in 160 men with ED and comorbid minor depression. 24 Patients were randomized to sildenafil or placebo for 12 weeks. An 'ED responder' was conservatively defined by a score of X22 on the erectile function domain (range 1-30) of the International Index of Erectile Function (IIEF) and affirmative responses to two questions regarding global improvement in erections and ability to have intercourse. Measures of depressive severity were significantly reduced in ED responders compared to ED nonresponders. Although the majority of men who were ED responders were in the sildenafil treatment group (83% vs 17%), it is interesting to note that even among the small number of ED responders treated with placebo, there were similar improvements in their depression scores.
Management of antidepressant-associated sexual dysfunction
Strategies for treating SSRI-induced sexual dysfunction include: (1) waiting for adaptation to develop; (2) switching to or augmenting with an antidepressant that does not have sexual side effects; (3) decreasing the dose and/or (4) adding an 'antidote'.
Adaptation appears to occur in less than 10% of patients and is therefore not a viable strategy. [25] [26] [27] Bupropion, nefazodone and mirtazapine (as well as agents not available in the US, such as tianeptine, amineptine, meclobemide and reboxetine) have lower rates of sexual dysfunction than SSRIs; switching to and augmenting with such agents has been shown to be useful in several studies. [28] [29] [30] [31] [32] As the effect on orgasm may be dose-dependent, strategies that involve reducing the serum level of an SSRI below an individual's threshold for orgasmic dysfunction can be effective. Such strategies include 'drug holidays'-in which a patient stops paroxetine or sertraline (i.e., the SSRIs with the shortest halflives) for 48 h and plans sexual activity to coincide with the serum trough; switching within SSRI class (which is generally effective only when the absolute serotonergic 5HT-2 activity is lowered) and lowering the SSRI dose. Most dose-reduction strategies entail some risk of depressive relapse.
Finally, 'antidote' strategies have been the subject of numerous case reports and open trials, but only limited systematic study. In theory, orgasm might be improved with medications that block 5HT-2 and 5HT-3 receptors, or enhance dopaminergic transmission. Indeed, the following agents have been studied as antidotes: the alpha 2 41 and other agents, such as Ginkgo biloba and l-arginine (which increase NO) 42 and the phosphodiesterase type 5 inhibitors sildenafil, tadalafil and vardenafil. 30, 43 Some agents with established antidepressant properties, such as bupropion, nefazodone and buspirone, may also be effective antidepressant augmentations, and improve sexual function indirectly via their effect on mood.
Seidman et al. 44 reported results from an open trial in which 21 men with SSRI-related ejaculatory delay were initially treated with usual doses of sildenafil, and in those with persistent DE, with higher dose sildenafil. They found that although usual doses were effective for ED, the majority of patients continued to experience ejaculatory delay. Ten men who had normal erectile function but persistent DE agreed to take higher sildenafil doses, either 150 or 200 mg. Nine (90%) reported a substantial clinical improvement in DE, suggesting that DE may require a higher sildenafil dose for response than does ED. Even so, response rates greater than 50% are typically reported for many 'antidotes' in open trials, yet do not generally hold up to systematic study. None has achieved widespread clinical acceptance, and none are FDAapproved for this purpose.
Placebo-controlled clinical trials of agents for SSRI-associated sexual dysfunction have been limited, and virtually none are generalizable to phasespecific SSRI-related ejaculatory delay. For example, Nurnberg et al. 45 randomized 90 men who were taking SSRIs and reported treatment-emergent sexual dysfunction to receive either sildenafil or placebo. Sildenafil administration was associated with improvement in sexual dysfunction. However, all of the enrolled men had multiple sexual problems at baseline (mean 3.5 problems). Thus, beyond the established efficacy of sildenafil for ED, specific improvement in DE could not be distinguished from improvement in erectile function. In other placebo-controlled studies in patients with SSRI-induced sexual dysfunction, Gingko biloba 46 and bupropion 47 were indistinguishable from placebo. In the one study that did show a positive sexual effect of bupropion compared to placebo, the effect was minimal and limited to libido. 39 
Conclusion
Despite its high prevalence and clinical importance, there is little known with confidence about antidepressant-associated DE. Evidence suggests that in a substantial proportion of men, there is a clear and direct causal relationship between SSRI use and DE. Yet, it must be recognized that depression and age are also associated with DE, and that whereas at least one-fourth of men develop DE on SSRIs, many do not. It is likely that in many men, the etiology of DE is multifactorial. Although we would predict that factors such as SSRI (vs other antidepressant), persistent depression, older age, ED and medical comorbidities (e.g., diabetes) might predict DE, there are virtually no systematically collected data specific to DE that address this issue. Finally, there exist a variety of possible remedies that may be safe and effective. Again, systematically collected data specific to DE are unavailable, though clinical consensus is that mirtazepine, bupropion and nefazodone cause less sexual dysfunction than other antidepressants.
